OTCMKTS:SHTDY Sinopharm Group (SHTDY) Stock Price, News & Analysis $9.43 0.00 (0.00%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividend About Sinopharm Group Stock (OTCMKTS:SHTDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sinopharm Group alerts:Sign Up Key Stats Today's Range$9.36▼$9.4750-Day Range$9.41▼$11.2352-Week Range$9.20▼$14.87Volume202,886 shsAverage Volume103,652 shsMarket CapitalizationN/AP/E Ratio1.89Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sinopharm Group Co., Ltd. is a China-based healthcare company focused primarily on pharmaceutical and medical product distribution. Through its distribution network, the company supplies prescription medicines, over-the-counter drugs, traditional Chinese medicines, medical devices and other healthcare products to hospitals, pharmacies, clinics and other healthcare institutions. The company also operates pharmaceutical retail businesses and provides related supply-chain, logistics and healthcare services. Its operations support the procurement, warehousing and delivery of medicines and medical products, while affiliated businesses are involved in pharmaceutical manufacturing and other healthcare activities. Sinopharm Group serves customers throughout mainland China and is part of China National Pharmaceutical Group Corporation, commonly known as Sinopharm, one of China's major state-owned healthcare enterprises. The company is headquartered in Shanghai and its shares are listed on the Hong Kong Stock Exchange, with American depositary shares traded over the counter in the United States.AI Generated. May Contain Errors. Read More Receive SHTDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SHTDY Stock News HeadlinesSHTDY - Sinopharm Group Co. Ltd.August 26, 2026 | seekingalpha.comSINOPHARM GRP CO UNSP/ADR by Sinopharm Group Co. Ltd. Stock Short Interest Report | OTC:SHTDY | BenzingaJuly 23, 2026 | benzinga.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 28 at 1:00 AM | Stansberry Research (Ad)Sinopharm Group Announces Executive Director ChangesNovember 6, 2025 | msn.comSinopharm Group Schedules Board Meeting to Review Interim ResultsAugust 13, 2025 | msn.comSinopharm Group Co. Ltd. ADR (SHTDY) Stock Price Today - WSJJuly 17, 2025 | wsj.comSinopharm Group Updates Final Dividend Distribution for 2024June 12, 2025 | tipranks.comSinopharm Group Co. Ltd. Reports Successful AGM and Shareholder MeetingsJune 12, 2025 | tipranks.comSee More Headlines SHTDY Stock Analysis - Frequently Asked Questions How have SHTDY shares performed this year? Sinopharm Group's stock was trading at $12.40 at the beginning of the year. Since then, SHTDY stock has decreased by 24.0% and is now trading at $9.43. How do I buy shares of Sinopharm Group? Shares of SHTDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryN/A Current SymbolOTCMKTS:SHTDY CIK1556605 Webwww.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees94,910Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.89 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:SHTDY) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinopharm Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.